Literature DB >> 17222501

The role of granulocytes following intravesical BCG prophylaxis.

Salvatore Siracusano1, Francesca Vita, Rita Abbate, Stefano Ciciliato, Violetta Borelli, Massimiliano Bernabei, Giuliano Zabucchi.   

Abstract

OBJECTIVES: The antitumour effect of bacillus Calmette-Guérin (BCG) still remains relatively undefined. Most investigations on its mechanism of action have focused on mononuclear cells; little consideration has been given to granulocytes. We analysed urine of patients with bladder cancer during 8 wk of intravesical BCG prophylaxis. The number of polymorphonuclear neutrophils (PMNs) and urothelial cells (UCs) was evaluated. We examined the in vitro response of the T24 UC line to human PMNs after BCG treatment.
METHODS: Seventeen patients were enrolled in the study. Cytologic analyses were performed on urine samples collected before each BCG instillation and after 2 h from the first voided urine after BCG instillation. Elastase activity was determined on these samples to evaluate PMN activation. PMN-induced damage was measured on the T24 cell line treated with BCG.
RESULTS: After BCG treatment, a large number of PMNs transmigrated through the urothelium and PMNs adherent to detached UCs were found. One patient, who did not respond with significant PMN transmigration, experienced recurrent disease. The number of eosinophils that transmigrated was low, with the exception of three patients with recurrent disease. In vitro, PMNs adhered to BCG-primed T24 cells and damaged the monolayer.
CONCLUSIONS: The results agree with recent evidence that PMNs may play an important role in the antitumour action of BCG during the BCG induction period. This role is probably nonspecific because both normal UCs in vivo and tumour cells in vitro appeared to be injured. As suggested by results obtained from a limited number of patients, a high number of eosinophils in the urine may indicate therapy failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17222501     DOI: 10.1016/j.eururo.2006.11.045

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

1.  Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Authors:  Romulus Breban; Aurelie Bisiaux; Claire Biot; Cyrill Rentsch; Philippe Bousso; Matthew L Albert
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  The role of HIF-1α in BCG-stimulated macrophages polarization and their tumoricidal effects in vitro.

Authors:  Pei Zhu; Yuyang Hou; Mengyan Tang; Zheng Jin; Youran Yu; Dong Li; Dongmei Yan; Zehua Dong
Journal:  Med Microbiol Immunol       Date:  2021-05-11       Impact factor: 3.402

3.  Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report.

Authors:  Mustafa Zafer Temiz; Aykut Colakerol; Ismail Ulus; Enes Kilic; Filip Paslanmaz; Sergen Sahin; Emrah Yuruk; Engin Kandirali; Atilla Semercioz; Ahmet Yaser Muslumanoglu
Journal:  Cancer Immunol Immunother       Date:  2020-07-22       Impact factor: 6.968

4.  The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

Authors:  Maximilian Burger; Nicolas Thiounn; Stefan Denzinger; Jozsef Kondas; Gerard Benoit; Manuel S Chapado; Fernando J Jimenz-Cruz; Laszlo Kisbenedek; Zoltán Szabo; Domján Zsolt; Marc O Grimm; Imre Romics; Joachim W Thüroff; Tamas Kiss; Bertrand Tombal; Manfred Wirth; Marc Munsell; Bonnie Mills; Tung Koh; Jeff Sherman
Journal:  J Transl Med       Date:  2010-06-08       Impact factor: 5.531

Review 5.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

6.  A survey on the distribution of healthy people with different anti-tumour ability.

Authors:  Yanhong Gao; Xiaolan Xu; Zhennan Dong; Chaoguang Jiang; Jin Gao; Jinchuan Hu; Junhao Gui; Haibao Wang; Yaping Tian
Journal:  Arch Med Sci       Date:  2010-10-26       Impact factor: 3.318

7.  Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.

Authors:  Claire Pieraerts; Virginie Martin; Patrice Jichlinski; Denise Nardelli-Haefliger; Laurent Derre
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

8.  Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).

Authors:  Marcia R Saban; Cindy Simpson; Carole Davis; Gemma Wallis; Nicholas Knowlton; Mark Barton Frank; Michael Centola; Randle M Gallucci; Ricardo Saban
Journal:  BMC Immunol       Date:  2007-05-16       Impact factor: 3.615

Review 9.  Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.

Authors:  Mikołaj Wołącewicz; Rafał Hrynkiewicz; Ewelina Grywalska; Tomasz Suchojad; Tomasz Leksowski; Jacek Roliński; Paulina Niedźwiedzka-Rystwej
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

10.  Study of tumor growth indicates the existence of an "immunological threshold" separating states of pro- and antitumoral peritumoral inflammation.

Authors:  Antonio Brú; David Gómez-Castro; Luis Vila; Isabel Brú; Juan Carlos Souto
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.